What is the role of placebo in neurotherapeutics?

References

• Benedetti F. Placebo effects: understanding the other side of medical care. 3rd ed. Oxford: Oxford University Press; 2021.
   Google Scholar
• Quattrone A, Barbagallo G, Cerasa A, et al. Neurobiology of placebo effect in Parkinson’s disease: what we have learned and where we are going. Mov Disord. 2018;33:1213–1227.
   PubMed Web of Science ®Google Scholar
• Lou JS. Placebo responses in Parkinson’s disease. Int Rev Neurobiol. 2020;153:187–211.
   PubMed Web of Science ®Google Scholar
• Witek N, Stebbins GT, Goetz CG. What influences placebo and nocebo responses in Parkinson’s disease? Mov Disord. 2018;33:1204–1212.
   PubMed Web of Science ®Google Scholar
• de La Fuente-fernández R, Lidstone S, Stoessl AJ. Placebo effect and dopamine release. J Neural Transm Suppl. 2006;70:415–418.
   Google Scholar
• Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015;84:794–802.
   PubMed Web of Science ®Google Scholar
• Mestre TA, Shah P, Marras C, et al. Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology. 2014;82:1402–1409.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Carlino E, Frisaldi E, et al. Placebo and nocebo responses in Parkinson’s disease. In: Martin CR, and Preedy VR, editors The Neuroscience of Parkinson’s Disease. Vol. 1, New York: Academic Press; 2020. p. 527–541.
   Google Scholar
• Frisaldi E, Zamfira DA, Benedetti F, et al. The subthalamic nucleus and the placebo effect in Parkinson’s disease. In: Swaab DF, Kreier F, Lucassen PJeditors. Handbook of Clinical Neurology: the Human Hypothalamus: middle and Posterior Region. San Diego: Elsevier BV; 2021. p. 433–446.
   Google Scholar
• Benedetti F, Barbiani D, Camerone E. Critical life functions: can placebo replace oxygen? Int Rev Neurobiol. 2018;138:201–218.
   PubMed Web of Science ®Google Scholar
• Piedimonte A, Barbiani D, Benedetti F, et al. The placebo effect in breath holding: a preliminary behavioral investigation. Neurosci Lett. 2020;739:135434.
   PubMed Web of Science ®Google Scholar
• Beedie CJ, Foad AJ. The placebo effect in sports performance: a brief review. Sports Med. 2009;39:313–329.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Pollo A, Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? J Neurosci. 2007;27:11934–11939.
   PubMed Web of Science ®Google Scholar
• Piedimonte A, Benedetti F, Carlino E. Placebo-induced decrease in fatigue: evidence for a central action on the preparatory phase of movement. Eur J Neurosci. 2015;41:492–497.
   PubMed Web of Science ®Google Scholar
• Benedetti F. Placebo and the new physiology of the doctor-patient relationship. Physiol Rev. 2013;93:1207–1246.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15:736–747.
   PubMed Web of Science ®Google Scholar
• Shaibani A, Frisaldi E, Benedetti F. Placebo response in pain, fatigue, and performance: possible implications for neuromuscular disorders. Muscle Nerve. 2017;56:358–367.
   PubMed Web of Science ®Google Scholar
• Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382:554–561.
   PubMed Web of Science ®Google Scholar
• Charlesworth JEG, Petkovic G, Kelley JM, et al. Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis. J Evid Based Med. 2017;10:97–107.
   PubMedGoogle Scholar
• Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375:686–695.
   PubMed Web of Science ®Google Scholar
• Bartfai T, Lees GV, Pharma TARP. A troubled asset relief program for novel, abandoned projects in the pharmaceutical industry. Sci World J. 2011;11:454–457.
   Google Scholar
• Dolgin E. Fluctuating baseline pain implicated in failure of clinical trials. Nat Med. 2010;16:1053.
   Web of Science ®Google Scholar
• Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology. 2008;70:263–272.
   PubMed Web of Science ®Google Scholar
• Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015;156:2616–2626.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840–1847.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65:S7–19.
   PubMed Web of Science ®Google Scholar
• Evers AWM, Colloca L, Blease C, et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother Psychosom. 2018;87:204–210.
   PubMed Web of Science ®Google Scholar
• Levine JD, Gordon NC, Fields HL. The mechanisms of placebo analgesia. Lancet. 1978;2:654–657.
   PubMed Web of Science ®Google Scholar
• Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci. 2015;16:403–418.
   PubMed Web of Science ®Google Scholar
• Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia: imaging a shared neuronal network. Science. 2002;295:1737–1740.
   PubMed Web of Science ®Google Scholar
• Zubieta JK, Bueller JA, Jackson LR, et al. Placebo effects mediated by endogenous opioid activity on μ-opioid receptors. J Neurosci. 2005;25:7754–7762.
   PubMed Web of Science ®Google Scholar
• Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63:533–543.
   PubMed Web of Science ®Google Scholar
• Zunhammer M, Bingel U, Wager TD, et al. Placebo effects on the neurologic pain signature: a meta-analysis of individual participant functional magnetic resonance imaging data. JAMA Neurol. 2018;75:1321–1330.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Frisaldi E, Barbiani D, et al. Nocebo and the contribution of psychosocial factors to the generation of pain. J Neural Transm. 2020;127:687–696.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Durando J, Vighetti S. Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway. Pain. 2014;155:921–928.
   PubMed Web of Science ®Google Scholar
• Tinnermann A, Geuter S, Sprenger C, et al. Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. Science. 2017;358:105–108.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Leurgans S, Raman R, et al. Objective changes in motor function during placebo treatment in PD. Neurology. 2000;54:710–714.
   PubMed Web of Science ®Google Scholar
• Shetty N, Friedman JH, Kieburtz K, et al. The placebo response in Parkinson’s disease. Parkinson study group. Clin Neuropharmacol. 1999;22:207–212.
   PubMed Web of Science ®Google Scholar
• Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson’s disease. Neurology. 1985;35:291–295.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson’s disease. Mov Disord. 2002;17:283–288.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson’s disease. Mov Disord. 2008;23:700–707.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23:690–699.
   PubMed Web of Science ®Google Scholar
• Watts RL, Freeman TB, Hauser RA, et al. A double-blind, randomised, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neurocelli-PD) vs. imitation surgery in patients with Parkinson’s disease (PD). Parkinsonism Rel Disord. 2001;7:87.
   Google Scholar
• Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54(3):403–414.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999;56:179–187.
   PubMed Web of Science ®Google Scholar
• de La Fuente-fernández R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science. 2001;293:1164–1166.
   PubMed Web of Science ®Google Scholar
• de La Fuente-fernández R, Phillips AG, Zamburlini M, et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res. 2002;136:359–363.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004;7:587–588.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Lanotte M, Colloca L, et al. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol. 2009;587:3869–3883.
   PubMed Web of Science ®Google Scholar
• Frisaldi E, Carlino E, Lanotte M, et al. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients. Cortex. 2014;60:3–9.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Frisaldi E, Carlino E, et al. Teaching neurons to respond to placebos. J Physiol. 2016;594:5647–5660.
   PubMed Web of Science ®Google Scholar
• Frisaldi E, Carlino E, Zibetti M, et al. The placebo effect on bradykinesia in Parkinson’s disease with and without prior drug conditioning. Mov Disord. 2017;32:1474–1478.
   PubMed Web of Science ®Google Scholar
• Jones BDM, Razza LB, Weissman CR, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Network Open. 2021;4:e2125531.
   PubMed Web of Science ®Google Scholar
• Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122–129.
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728–737.
   PubMed Web of Science ®Google Scholar
• Faria V, Appel L, Åhs F, et al. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology. 2012;37:2222–2232.
   PubMed Web of Science ®Google Scholar
• Faria V, Åhs F, Appel L, et al. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. Int J Neuropsychopharmacol. 2014;17:1149–1157.
   PubMed Web of Science ®Google Scholar
• Tekampe J, van Middendorp H, Meeuwis SH, et al. Conditioning immune and endocrine parameters in humans: a systematic review. Psychother Psychosom. 2017;86:99–107.
   PubMed Web of Science ®Google Scholar
• Tekampe J, van Middendorp H, Sweep FCGJ, et al. Human pharmacological conditioning of the immune and endocrine system: challenges and opportunities. Int Rev Neurobiol. 2018;138:61–80.
   PubMed Web of Science ®Google Scholar
• Hadamitzky M, Sondermann W, Benson S, et al. Placebo effects in the immune system. Int Rev Neurobiol. 2018;138:39–59.
   PubMed Web of Science ®Google Scholar
• Goebel MU, Trebst AE, Steiner J, et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 2002;16:1869–1873.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Pollo A, Lopiano L, et al. Conscious expectation and unconscious conditioning in analgesic, motor and hormonal placebo–nocebo responses. J Neurosci. 2003;23:4315–4323.
   PubMed Web of Science ®Google Scholar
• Hall KT, Loscalzo J, Kaptchuk T. Pharmacogenomics and the placebo response. ACS Chem Neurosci. 2018;9:633–635.
   PubMed Web of Science ®Google Scholar
• Colloca L, Wang Y, Martinez PE, et al. OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia. Pain. 2019;160:1824–1834.
   PubMed Web of Science ®Google Scholar
• Furmark T, Appel L, Henningsson S, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci. 2008;28:13066–13074.
   PubMed Web of Science ®Google Scholar
• Leuchter AF, McCracken JT, Hunter AM, et al. Monoamine oxidase a and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol. 2009;29:372–377.
   PubMed Web of Science ®Google Scholar
• Hall KT, Lembo AJ, Kirsch I, et al. Catechol-O-Methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012;7:e48135.
   PubMed Web of Science ®Google Scholar
• Colloca L, Lopiano L, Lanotte M, et al. Overt versus covert treatment for pain, anxiety and Parkinson’s disease. Lancet Neurol. 2004;3:679–684.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Carlino E, Pollo A. Hidden administration of drugs. Clin Pharmacol Ther. 2011;90:651–661.
   PubMed Web of Science ®Google Scholar
• Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature. 1984;312:755–756.
   PubMed Web of Science ®Google Scholar
• Levine JD, Gordon NC, Smith R, et al. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain. 1981;10:379–389.
   PubMed Web of Science ®Google Scholar
• Amanzio M, Pollo A, Maggi G, et al. Response variability to analgesics: a role for non- specific activation of endogenous opioids. Pain. 2001;90:205–215.
   PubMed Web of Science ®Google Scholar
• Bingel U, Wanigasekera V, Wiech K, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3:70ra14.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer’s disease makes analgesic therapies less effective. Pain. 2006;121:133–144.
   PubMed Web of Science ®Google Scholar
• Stein N, Sprenger C, Scholz J, et al. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain. 2012;153:2210–2217.
   PubMed Web of Science ®Google Scholar
• Krummenacher P, Candia V, Folkers G, et al. Prefrontal cortex modulates placebo analgesia. Pain. 2010;148:368–374.
   PubMed Web of Science ®Google Scholar
• Berger JT. Placebo medication use in patient care: a survey of medical interns. West J Med. 1999;170:93–96.
   PubMedGoogle Scholar
• Hrobjartsson A, Norup M. The use of placebo interventions in medical practice – a national questionnaire survey of Danish clinicians. Eval Health Prof. 2003;26:153–165.
   PubMed Web of Science ®Google Scholar
• Nitzan U, Lichtenberg P. Questionnaire survey on use of placebo. Br Med J. 2004;329:944–946.
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Hallett M, Jankovic J. Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019;127:32–44.
   PubMed Web of Science ®Google Scholar
• Mariani LL, Corvol JC. Maximizing placebo response in neurological clinical practice. Int Rev Neurobiol. 2020;153:71–101.
   PubMed Web of Science ®Google Scholar